Hey as much as I would like that to be the case Elzephyrus I cant see it being that high maybe revenue for the quarter but not cash receipts. I didnt go to the Sydney meeting but some of the posters who did are basing their assumptions lower based on what was said at meeting eg taking out the dead wood getting rid of unproductive clients etc so based on that I guess we wont see $11 mill in cash receipts based on fact sales have increased a hell of a lot in last couple of months of quarter but probably havent got the cash yet from that(depending on payment terms). . I would be happy with between 7 and 8 million.
I would like to see a real detailed activities report. I also think the cash wont be as high as the market is saying it wont by lack of buying interest. Yes I know how can anyone know etc beforehand but it is uncanny how often buying before a 4c can be correlated to what is in a 4c for a lot of companies on the ASX IMO. Now I am not suggesting anything untoward its just how it is.
I just hope they hurry up and release the damn thing and start releasing solid news that we have been waiting on for months eg UL certifcation eg electronics, Military, Licensing etc
As for Nasdaq listing there are no new applications or forms under Alexium through SEC so I still think its a way off yet. Personally if we are seeing good numbers in the yearly report, 4cs etc eg if people can see the cash listing may not be such a bad thing. Vastly different to when a a company like PRR lists which had no revenue still in proving up their product etc still going through medical trials etc to a company with increasing revenue, increasing sales etc. I feel if they can see growth and Value then the listing may go better than what we all think anyway just my ramblings after a busy work weekend GLTA. Hoping the 4c comes out this week as it was mentioned in the Tim Boreham article that it would be released this week however the 31st is Monday next week so it could be delayed till then
All my view so stand to be corrected on anything
- Forums
- ASX - By Stock
- AJX
- Q4 cash receipts
Q4 cash receipts, page-15
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AJX (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.73M |
Open | High | Low | Value | Volume |
1.1¢ | 1.1¢ | 1.0¢ | $15.27K | 1.523M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1556203 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 94595 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1556203 | 0.010 |
6 | 519629 | 0.009 |
3 | 610000 | 0.008 |
2 | 240000 | 0.007 |
3 | 516888 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 94595 | 2 |
0.012 | 163531 | 4 |
0.014 | 137511 | 2 |
0.015 | 129929 | 2 |
0.016 | 5328505 | 2 |
Last trade - 11.52am 12/11/2024 (20 minute delay) ? |
Featured News
AJX (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online